Abstract: Lobaplatin（LBP） is the third generation of platinum anticancer drugs. Experimental study showed that LBP has the exact antitumor activity in nonsmall cell lung cancer（NSCLC），which is similar to cisplatin（PDD），better than carboplatin（Cab） and can overcome PDD resistance； associated with NSCLC commonly used drugs showed certain advantages， especially with antimicrotubule drugs. Clinically， the regimen composed of LBP achieved good effect in the firstline treatment， maintenance treatment and second-line treatment， which is similar to the regimen composed PDD， but the tolerance is better， enriched the choice of platinum drugs in advanced NSCLC. However， LBP in the treatment of advanced NSCLC lack of sufficient evidencebased medical evidence， needs strengthened researchs， especially the large sample， multicenter and randomized prospective studies.